Molecular docking of ferulic acid analogue compounds against epidermal growth factor receptor as a potential therapy for breast cancer
DOI:
https://doi.org/10.46542/pe.2024.243.185190Keywords:
Breast cancer, Epidermal growth factor receptor, Ferulic acid, Good health, Triple-negative breast cancer, Well-beingAbstract
Background: Triple-negative breast cancer (TNBC) accounted for 18.1% of the breast cancer cases that occurred in Indonesia until 2020. Epidermal growth factor receptor (EGFR) overexpression is found in at least 50% of TNBC cases. So far, it is necessary to find an anti-cancer compound that has the potential against TNBC-type breast cancer to achieve good health and well-being.
Objective: Ferulic acid derivatives were designed to be active on EGFR in silico study.
Methods: Molecular docking was performed using Auto Dock 1.5.7 and PyRx 0.8 software, and visualisation was observed using Discovery Studio. FA ligand and its four derivatives were docked into the receptor EGFR (PDB ID: 3W33).
Results: It was found that ferulic acid derivatives have high potential as an anticancer through EGFR inhibition in TNBC-type breast cancer. 4-(4-methyl) benzoyloxy-3-methoxycinnamic acid had the best potential among other derivatives, which showed the lowest binding free energy of -8.81 kcal/mol and the smallest Ki of 352.65nM. Methyl substitution at the benzoyloxy increased ligand interaction with amino acids in EGFR by increasing hydrophobic π-alkyl, π-π and alkyl binding with amino acids.
Conclusion: The 4-(4-methyl) benzoyloxy-3-methoxycinnamic acid was the most prospective compound as an EGFR inhibitor and predicted as the most potential compound against breast cancer.
References
Ali, R., & Wendt, M. K. (2017). The paradoxical functions of EGFR during breast cancer progression. Signal transduction and targeted therapy, 2, 16042. https://doi.org/10.1038/sigtrans.2016.42
Arnold, M., Morgan, E., Rumgay, H., Mafra, A., Singh, D., Laversanne, M., Vignat, J., Gralow, J. R., Cardoso, F., Siesling, S., & Soerjomataram, I. (2022). Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast, 66, 15–23. https://doi.org/10.1016/j.breast.2022.08.010
Li, J., Zhou, N., Luo, K., Zhang, W., Li, X., Wu, C., & Bao, J. (2014). In silico discovery of potential VEGFR-2 inhibitors from natural derivatives for anti-angiogenesis therapy. International journal of molecular sciences, 15(9), 15994–16011. https://doi.org/10.3390/ijms150915994
Butti, R., Das, S., Gunasekaran, V. P., Yadav, A. S., Kumar, D., & Kundu, G. C. (2018). Receptor tyrosine kinases (RTKs) in breast cancer: Signaling, therapeutic implications and challenges. Molecular Cancer, 17(34), 1–18. https://doi.org/10.1186/s12943-018-0797-x
Centers for Disease Control and Prevention. (2021). COVID-19. https://www.cdc.gov/coronavirus/2019-nc ov/prevent-getting-sick/prevention.html
Ekowati, J., Diyah, N. W., Nofianti, K. A., Hamid, I. S., & Siswandono, S. (2018). Molecular docking of ferulic acid derivatives on P2Y12 receptor and their ADMET prediction. Journal of Mathematical and Fundamental Sciences. 50(2), 203–219. https://doi.org/10.5614/j.math.fund.sci.2018.50.2.8
Hashmi, A. A., Naz, S., Hashmi, S. K., Irfan, M., Hussain, Z. F., Khan, E. Y., Asif, H., & Faridi, N. (2019). Epidermal growth factor receptor (EGFR) overexpression in triple-negative breast cancer: association with clinicopathologic features and prognostic parameters. Surgical and Experimental Pathology, 2(6), 1–7. https://doi.org/10.1186/s42047-018-0029-0
Katzung, B. G. (2018). Basic clinical pharmacology 14th Edition. McGraw Education.
Kinch, M. S., Kraft, Z., & Schwartz, T. (2022). 2021 in review: FDA approvals of new medicines. Drug discovery today, 27(8), 2057–2064. https://doi.org/10.1016/j.drudis.2022.04.010
The Ministry of Health of the Republic of Indonesia. (2022). The most common breast cancer in Indonesia, the ministry of health targets equalisation of health services. https://sehatnegeriku.kemkes.go.id/baca/umum/20220202/1639254/kanker-payudaya-paling-banyak-di-indonesia-kemenkes-targetkan-pemerataan-layanan-kesehatan/
Nakai, K., Hung, M. C., & Yamaguchi, H. (2016). A perspective on anti-EGFR therapies targeting triple-negative breast cancer. American journal of cancer research, 6(8), 1609–1623.
Serafim, T. L., Carvalho, F. S., Marques, M. P., Calheiros, R., Silva, T., Garrido, J., Milhazes, N., Borges, F., Roleira, F., Silva, E. T., Holy, J., & Oliveira, P. J. (2011). Lipophilic caffeic and ferulic acid derivatives presenting cytotoxicity against human breast cancer cells. Chemical research in toxicology, 24(5), 763–774. https://doi.org/10.1021/tx200126r
Serafim, T.L., Milhazes, N., Borges, F., Oliveira, P.J. (2015). Caffeic and ferulic acid derivatives: Use in breast cancer, coffee in health and disease prevention. Elsevier Inc.
Siswandono. (2014). Pengembangan Obat Baru. Airlangga University Press.
Siswandono (Ed). (2016). Kimia medisinaI, Edisi Ke-2. Airlangga University Press.
Sudhagar, S., Sathya, S., Anuradha, R., Gokulapriya, G., Geetharani, Y., & Lakshmi, B. S. (2018). Inhibition of epidermal growth factor receptor by ferulic acid and 4-vinylguaiacol in human breast cancer cells. Biotechnology Letters, 40, 257–262. https://doi.org/10.1007/s10529-017-2475-2
Surabhi & Singh, B.K. (2018). Computer aided drug design: an overview. Journal of Drug Delivery & Therapeutics, 8(5): 504–509. https://doi.org/10.22270/jddt.v8i5.1894
Susanti, N. M. P., Laksmiani, N. P. L., Noviyanti, N. K. M., Arianti, K. M., & Duantara, I. K. (2019). Molecular docking of terpinen-4-Ol as anti-inflammatory on atherosclerosis through in silico. Journal of Chemistry, 13(2), 221–228. https://doi.org/10.24843/JCHEM.2019.v13.i02.p16
van Tonder, J. J., Steenkamp, V., & Gulumi, M. (2013). Pre-clinical assessment of the potential intrinsic hepatotoxicity of candidate drugs. InTech. https://doi.org/10.5772/54792
Widiana, I. K., & Irawan, H. (2020). Clinical and subtypes of breast cancer in Indonesia. Asian Pacific Journal of Cancer Care, 5(4), 281–285. https://doi.org/10.31557/APJCC.2020.5.4.281-285
